期刊文献+

血管紧张素受体拮抗剂在糖尿病肾病治疗中的作用 被引量:3

暂未订购
导出
摘要 糖尿病肾病的防治是糖尿病慢性并发症防治研究的一项重要课题。研究显示 ,血管紧张素受体拮抗剂能够降低尿蛋白排泄量 ,延缓肾动脉硬化及肾脏纤维化的进展 ,对肾脏具有显著的保护作用。目前认为 ,这一作用是通过多种途径实现的 ,除降低血压带来的益处外 ,还存在非血流动力学方面的作用 ,如抑制细胞外基质在肾脏局部的积聚、下调肾脏皮质转化生长因子 β的表达、减少肾脏细胞凋亡、改善肾组织的高代谢状态和抗过氧化酶活性等。近年来 。
作者 曹宏 刘超
出处 《国外医学(药学分册)》 2003年第5期288-291,共4页 Foreign Medical Sciences(Section of Pharmarcy)
  • 相关文献

参考文献18

  • 1Mastusaka T, Hymes J, Ichikawa I. Angiotemin ir progressive renal disease: theory and practice [ J ]. J Am Soc Nephrol, 1996, 7(10) :2025 - 2043.
  • 2Leehey DJ, Singh AK, Alavi N, et al. Role of angiotensin Ⅱ in diabetic nephropathy[J]. Kidney Int, 2000, 77(Suppl) : S93 - S98.
  • 3Border WA, Noble NA. Evidence that TGF-β should be a therapeutic target in diabetic nephropathy[J]. Kidney Int,1998, 54(4) : 1390- 1391.
  • 4Shihab FS, Bennett WM. Angiotensin Ⅱ blockade decrease TGF-β1 and matrix proteins in cyclosporine nephropathy[J].Kidney Int, 1997, 52(3) :660- 673.
  • 5Chatterjee PK, Weerackody RP, Mistry SK, et al. Selective antagonism of the AT1 receptor inhibits angitensin Ⅱ stimulated DNA and protein synthesis in primary cultures of human proximal tubular cells[J]. Kidney Int, 1997, 52(3) :699 - 705.
  • 6Junaid A, Rosenbers ME, Hostetter TH. Interaction of angiotensin Ⅱ and TGF-β1 in the rat remnant kidney[J]. J Am Soc Nephrol, 1997, 8(11):1732- 1738.
  • 7Hirano T, Kashiwazaki K, Moritomo Y, et al. Albuminuria is directly associated with increased plasma PAI-1 and factor levels in NIDDM patients[J]. Diabetes Res Clin Pract,1997, 36(1):11 - 18.
  • 8Rovin BH, Doe N, Tan LC. Monocyte chemoattractant protein-1 levels in patients with glomerular disease [ J]. Am J Kudbey Dis, 1996, 27(5) :640- 646.
  • 9Zhang W, Khanna P, Chan LL, et al. Diabetes-induced apoptosis in rat kidney[J]. Biochem Mol Med, 1997, 61(1) :58- 62.
  • 10Cigola E, Kajstura J, Li B, et al. Angiotensin Ⅱ activates programmed myocyte cell death in vitro [ J ]. Exp Cell Res,1997, 231(2) :363 - 371.

同被引文献8

  • 1罗昱澜,刘皋林,缪海均.洛沙坦治疗糖尿病肾病的研究进展[J].中国医院药学杂志,2005,25(7):659-661. 被引量:2
  • 2Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [ J ]. N Engl J Med, 2001,345 ( 12 ) : 861 - 869.
  • 3l,ewis E J, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes[ J]. N Engl J Med,2001,345 (12) :851 -860.
  • 4Andersen S, Tarnow L, Rossing P, et al. Renoprotective effects of angiotcnsin Ⅱ receptor blockade in type 1 diabetic patients with diabetic nephropathy [ J ]. Kidney Int, 2000,57 (2) :601 - 606.
  • 5Roppin J, Bain SC, Barnett AH. DETAIL sutdy Jrationale and de- sign of diabetics exposed to telmisartan and enalapril (dDE- TAIL) study[ J]. Diabetes Complications, 2002,16(3 ) : 195.
  • 6Brenner BM, Cooper ME, Zeeuw Dd D, et al. The losartan renal protection study-rationale study design and baseline characterlsticsof RENALL( reduction of endpoints in NIDDM with the angio- tensin II antagonist losartan) [ J ]. Jrenin Angiotensin Aldosterone Syst,2000, ( 1 ) :328.
  • 7乐伟波,刘志红.肾素-血管紧张素系统与糖尿病肾病[J].肾脏病与透析肾移植杂志,2008,17(4):369-373. 被引量:12
  • 8林善锬.糖尿病肾病发病机制的研究进展[J].中华内科杂志,2001,40(11):782-783. 被引量:103

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部